首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer journal

缩写:CANCER J

ISSN:1528-9117

e-ISSN:1540-336X

IF/分区:2.1/Q3

文章目录 更多期刊信息

共收录本刊相关文章索引1187条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Brian J Sworder,Alex H Herrera Brian J Sworder
Emerging treatment paradigms in classic Hodgkin lymphoma (cHL), which increasingly incorporate immunotherapy and response-adapted strategies, have increased the need for more accurate disease assessment tools. PET/CT remains the cornerstone...
Christopher R D&#x;Angelo,James O Armitage,Matthew L Lunning Christopher R D&#x;Angelo
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma subtype, representing a small fraction of Hodgkin lymphoma or an even smaller fraction of B-cell non-Hodgkin lymphoma, depending on the classification schema used. N...
Thomas Lucido,Robert Ryan,Sara Sawicki et al. Thomas Lucido et al.
This review summarizes contemporary management of Classic Hodgkin Lymphoma in special clinical situations, with a focus on integrating primary clinical trial and observational data to inform individualized treatment decisions. The emphasis ...
Meghana Subramanian,Andrew Evens,Joanna M Rhodes Meghana Subramanian
Older patients age >60 years with advanced-stage cHL have historically had poorer outcomes, attributed to comorbid conditions, performance status, and chemotherapy intolerance. The use of an anthracycline-based chemotherapy backbone has sho...
Brittany C Kimball,Allison C Rosenthal Brittany C Kimball
Hodgkin lymphoma is one of the most common cancers in adolescents and young adults (AYAs), a population with distinct biological, clinical, and developmental characteristics. Yet care remains fragmented between pediatric and adult systems c...
Kento Kawai,Neha Akkad,Christopher Flowers Kento Kawai
Management of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved substantially with the integration of novel targeted and immune-based therapies. Agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CP...
Joseph Carmicheal,Charles Enke Joseph Carmicheal
Radiation therapy (RT) has long been an important part of the history of curative treatment for Hodgkin Lymphoma since the pioneering work of Vera Peters, MD and Henry Kaplan, MD. The contemporary role of radiation therapy in the management...
Kelsey Baron,Boyu Hu Kelsey Baron
Before 1970, Hodgkin lymphoma (HL) was an often-fatal lymphoma treated with radiation and/or single-agent chemotherapy. In contrast, HL is now a largely curable disease treated with multiagent chemotherapy regimens. In the intervening half-...
Kishan Patel,Varun Iyengar,Alison Moskowitz Kishan Patel
Combined modality therapy (CMT; chemotherapy with consolidative radiation) has led to excellent long-term outcomes in patients with early-stage Hodgkin lymphoma. However, despite high cure rates, CMT can lead to significant long-term toxici...